Labaru

Xinhua | An sabunta: 2020-11-11 09:20

Ana nuna alamar fayil: Eli Lilly Logo a daya daga cikin ofisoshin kamfanin a San Diego, California, Amurka, Satumba 1720. [Hoto / hukumomi]
Washington - Gudanar da Abinci da Magunguna na Amurka ya ba da izinin gaggawa na gaggawa (EUA) don maganin monocid-16 a-matsakaici Covid-19 a cikin marasa lafiya da marasa lafiya.

Magungunan, Bamlanvimab, an ba da izini donClovid-19 marasa lafiyaSu wanene shekaru 12 da haihuwa suna yin la'akari da kilogram 40, kuma waɗanda suke cikin haɗari don ci gaba zuwa asibitoci mai ƙarfi-19 da (ko) asibiti, bisa ga wata hanyar FDA ranar Litinin.

Wannan ya hada da wadanda ke shekaru 65 ko sama da haka, ko kuma wa ke da wasu yanayin likita.

Abubuwan ƙwadun ƙwayar moniclonal sune sunadaran dakin gwaje-gwaje ne waɗanda ke kwaikwayon ikon rigakafi na yin yaƙi da maganin rigakafi kamar ƙwayoyin cuta. Bamlanvimab antilonal ne wanda aka yiwa musamman da aka yiwa karar furotin na srs-Cov-2, wanda aka tsara don toshe abin da aka makala da kuma shigarwa cikin sel mutane.

Yayinda ake nuna aminci da tasirin wannan bincike na bincike a cikin gwaji na asibiti don rage asibitoci na cutar a cikin kwanaki 28 bayan an kwatanta shi da yanayin Clovid a cikin kwanaki 28 bayan an kwatanta shi da yanayin Clovid a cikin kwanaki 28 bayan an kwatanta shi da yanayin Clovid a cikin kwanaki 28 bayan an kwatanta shi da Wearbo, in ji FDA.

Bayanan da ke tallafawa EUA na Bamotizer sun dogara ne akan wani lokaci guda biyu, makafi biyu a cikin tsoffin alamu na matsakaici.

Daga cikin wadannan marasa lafiya, 101 sun karbi kashi 700-na Milgitrab kashi 7,800-Milggram, 101 sun samu wani samfurin asibiti na 7,000-Cov-2 ko bidiyo mai zagin yanar gizo.

Don marasa lafiya a hadarin cuta don cutar da cuta, asibitoci da dakin gaggawa (er) ya faru cikin 3 bisa dari na marasa lafiya mai ɗorewa.

Tasirin kan nauyin bidiyo da kuma rage ƙwazo a asibiti da er, kuma a kan aminci, kuma suna kama da wasu allurai uku Bamanivimab alles, a cewar FDA.

EUA ta ba Bamalivimab da za a rarraba kuma a gudanar da su azaman kashi ɗaya cikin abubuwan da suka dace da masu kula da lafiya.

Pamsiziavimab tana ba da ƙwararrun masu kula da lafiya a kan gaban wannan kayan aikin na 19, "in ji Patemicing Cibiyar FDA na 19," in ji Patemicing Cibiyar FDA na 19, "in ji cibiyar ta FDA ta hanyar kimantawa miyagun ƙwayoyi da bincike. "Za mu ci gaba da kimanta sabon bayanai kan aminci da ingancin Bamlananicimab yayin da suke samuwa."

Dangane da tsallaka na tabbacin shaidar shaidar da ake samu, FDA ta yanke shawarar yin imani da Bamallavimab na iya yin tasiri a cikin marasa lafiya marasa lafiya ko matsakaici-19. Kuma, lokacin da aka yi amfani da shi don kula da COVID-19 ga yawan adadin da aka ba da izini, sanannun fa'idodi da mahimman haɗarin da aka sani da miyagun ƙwayoyi, a cewar FDA.

Abubuwa masu illa na Bamallavimab sun haɗa da ANAPHYLAXIS da kuma jiko na jiko, tashin zuciya, da gudawa, itching da amai, a cewar hukumar.

Kasar EUA ta zo kamar yadda Amurka ta zarce da Amurka miliyan 10 da COVID-19 kwanaki 10 ne kawai bayan buga miliyan 9. Yawan adadin cututtukan yau da kullun na kwanan nan sun wuce 100,000, kuma masana kiwon lafiyar jama'a sun yi gargadin cewa kasar ta shiga matakin mafi muni na Pandemic.